CD274 and neoplasm: (121) found that in BRCA1-deficient ovarian cancer mice, olaparib can trigger local and systemic anti-tumor immune responses, activate the STING pathway and upregulate PD-L1 expression; and when combined with PD-1 inhibitors, this immune triggering effect is further enhanced, resulting in stronger inhibition of tumor cell growth in nude mice, significantly prolonging the survival of the mice.